Last reviewed · How we verify
NCT03953911
Increasing HPV Vaccination Rates Via Educational Interventions in Schools Located Within Cedars-Sinai Catchment Areas
EARLY_PHASE1 trial testing Mobile Clinic in Human Papilloma Virus in 3 participants. Status unknown.
27 May 2020
Quick facts
| Lead sponsor | Cedars-Sinai Medical Center |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | prevention |
| Enrollment | 3 |
| Start date | 28 May 2019 |
| Primary completion | 27 May 2020 |
| Estimated completion | 30 June 2020 |
Drugs / interventions tested
- Mobile Clinic — full drug profile →
- Educational Sessions for Parents
Conditions studied
- Human Papilloma Virus — all drugs for Human Papilloma Virus →
- HPV Vaccination — all drugs for HPV Vaccination →
- Health Education — all drugs for Health Education →
Sponsor
Cedars-Sinai Medical Center
Who can join
Adults 11 to 13, any sex, with Human Papilloma Virus or HPV Vaccination. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Infections with human papillomavirus (HPV) can cause cancer of the cervix, vagina, anus, throat, mouth, and penis. Prevention of these HPV-related cancers could be achieved by immunization with the nonavalent (HPV6,11,16,18,31,33,45,52,58) vaccine currently commercially available. However, in the U.S. approximately only 30% of females and 20% of males in the recommended age group receive the complete, three-dose HPV vaccine. Furthermore, data from the Los Angeles county suggest that HPV vaccination rates among these groups are lower than the national average. Significant barriers clearly remain including knowledge of the vaccine, transportation, number of doses and concern of side effects. Several programs worldwide have shown that schools remain an important venue for education as well as vaccination. In the US, vaccination within schools remains difficult because of many barriers including lack of nursing, insurance reimbursement, and liability. However, the school remains an important access to educational formats. The objective of this study is to evaluate the effectiveness of educational sessions on the HPV vaccine among parents with children of vaccination age as a strategy to increase HPV vaccine uptake, by comparing HPV vaccination rates before and after the intervention. It is hypothesized HPV vaccine uptake will improve through the receipt of educational sessions to the parents of middle school children about the importance of the anti-cancer vaccine, the HPV vaccine. Three schools within Cedars-Sinai catchment area with whom Cedars-Sinai already has a Memorandum of Understanding in place: Berendo, Drew, and Carver Middle Schools in Los Angeles (SPA 4, SPA 6) will be recruited to the study. HPV vaccination rates will be compared before and after the intervention at the end of the observation period (12 months).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03953911
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Human Papilloma Virus
Currently open trials in the same condition.
- NCT07336134 — PopSci CHW4CervixHealth · NA · recruiting
- NCT06414057 — HPV Equity Study: Exploring Cervical Cancer Control in Scotland for Women With Experience of Priority Risks · recruiting
- NCT06747390 — Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery · Phase 1 · recruiting
- NCT06598176 — Developing a Combined Molecular Screening and Triage Test for Cervical Cancer in Self-samples · NA · recruiting
- NCT05996783 — Cervical Cancer Screening Based on First-void Urine Self-sampling to Reach un(Der)-Screened Women: ScreenUrSelf Trial · NA · active not recruiting
Other Cedars-Sinai Medical Center trials
Trials by the same sponsor.
- NCT06012487 — Correlates and Control of Blood Pressure Variability · Phase 1 · not yet recruiting
- NCT07495995 — SAMe for Prevention of Liver Cancer in MASLD-Related Cirrhosis · Phase 2 · not yet recruiting
- NCT07413965 — TAVR vs SAVR in Severe Bicuspid Aortic Stenosis · NA · not yet recruiting
- NCT06521021 — CHOICE to AVOID or RESIST · NA · not yet recruiting
- NCT07499089 — Together-Breast Cancer Support Platform · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03953911 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cedars-Sinai Medical Center
- Last refreshed: 17 May 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03953911.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing